阿利西尤单抗结合阿托伐他汀治疗ST段抬高型心肌梗死的疗效及对患者血脂、心功能的影响

Efficacy of Alirocumab Combined with Atorvastatin in the Treatment of ST Segment Elevation Myocardial Infarction and Its Effect on Blood Lipid and Heart Function

目的探讨阿利西尤单抗结合阿托伐他汀治疗ST段抬高型心肌梗死的疗效及对患者血脂、心功能的影响。方法选取2021年1月至2022年11月景德镇市第二人民医院收治的70例ST段抬高型心肌梗死患者为研究对象,按照随机数字表法分为对照组和观察组,每组各35例。对照组给予阿托伐他汀治疗,观察组于此基础上加用阿利西尤单抗治疗。对比两组患者的临床疗效、血脂水平、心功能指标。结果观察组临床治疗总有效率88.57%,高于对照组的62.86%(P<0.05)。观察组的低密度脂蛋白胆固醇(1.97±0.35)mmol/L、三酰甘油(1.30±0.52)mmol/L、左心室收缩末期内径(38.09±3.97)mm、左心室舒张末期内径(47.31±9.28)mm均低于对照组的(3.11±0.69)mmol/L、(1.58±0.63)mmol/L、(41.71±4.21)mm、(51.93±9.84)mm;观察组的左心室射血分数(62.01±6.35)%高于对照组的(50.39±5.68)%,均差异有统计学意义(均P<0.05)。结论采用阿利西尤单抗结合阿托伐他汀治疗ST段抬高型心肌梗死患者效果显著,可显著改善ST段抬高型心肌梗死患者机体内血脂代谢水平及心功能。

Objective To explore the therapeutic effect of alirocumab combined with atorvastatin in the treatment of ST segment elevation myocardial infarction and its impact on blood lipids and cardiac function in patients.Methods 70 patients with ST segment elevation myocardial infarction admitted to The Second People's Hospital of Jingdezhen from January 2021 to November 2022 were selected as the study subjects.They were randomly divided into a control group and an observation group using random number table method,with 35 patients in each group.The control group was treated with atorvastatin,while the observation group were treated with alirocumab on basis of the control group.Compare the clinical efficacy,blood lipid levels,and cardiac function indicators between the two groups of patients.Results The total effective rate of clinical treatment in the observation group was 88.57%,which was higher than 62.86%in the control group,with a statistically significant difference(P<0.05).The low density lipoprotein cholesterol(1.97±0.35)mmol/L,triglyceride(1.30±0.52)mmol/L,left ventricular end systolic diameter(38.09±3.97)mm,and left ventricular end diastolic diameter(47.31±9.28)mm in the observation group were lower than those in the control group(3.11±0.69)mmol/L,(1.58±0.63)mmol/L,(41.71±4.21)mm,and(51.93±9.84)mm,The left ventricular ejection fraction of the observation group(62.01±6.35)%was higher than that of the control group(50.39±5.68)%,with a statistically significant difference(P<0.05).Conclusion The combination of alirocumab and atorvastatin has a significant therapeutic effect on patients with ST segment elevation myocardial infarction,which can significantly improve the levels of blood lipid metabolism and cardiac function in the body of ST segment elevation myocardial infarction patients.